CYTK (Cytokinetics) Short Percentage of Float


CYTK Cytokinetics Inc CYTK
51 GF Score
Price $84.88
GF Value $250.73
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is Cytokinetics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

CYTK vs ARWR, TECH, KRYS: Short Percentage of Float Comparison

For the Biotechnology subindustry, Cytokinetics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cytokinetics Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytokinetics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Cytokinetics's Short Percentage of Float falls into.


CYTK
51GF Score
Cytokinetics Inc CYTK
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cytokinetics (CYTK) Overvalued in 2026?

Based on GuruFocus' analysis, Cytokinetics stock appears to be undervalued. The current stock price of $84.88 is trading 66.1% below its estimated GF Value™ of $250.73. GuruFocus considers Cytokinetics to be Possible Value Trap.

Key valuation signals for CYTK:

  • Short Percentage of Float:
  • GF Value™: $250.73 vs. price of $84.88 (66.1% below fair value)
  • GF Score™: 51/100 with 8 warning signs

No single metric tells the full story. See the CYTK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cytokinetics Business Description

Other Exchanges 1CYTK:ItalyKK3A:Germany
Address 350 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
51GF Score

Get the complete analysis for CYTK

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$84.88
Price
$250.73
GF Value